Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...

Investorideas , a global news source and expert investing resource, announces today's roundup of <a target=_blank href= ...

We spoke with Dr. Demetre Daskalakis, the director of the CDC’s National Center for Immunization and Respiratory Diseases, about the agency’s avian flu response.

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement ...

Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

USA: A recent narrative review has highlighted the effectiveness of GLP-1 receptor agonists (RAs) in treating type 2 diabetes ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...